2-PYRIDINONE DERIVATIVES, HAVING HIV INHIBITING PROPERTIES

2-PYRIDINONE DERIVATIVES, HAVING HIV INHIBITING PROPERTIES

The present invention relates to 2-Pyridinone derivatives, more specifically 5-ethyl-6-methyl-2-pyridinone derivatives, according to general formula I that inhibit human immunodeficiency virus type 1 (HIV-1) replication and are therefore of interest in the treatment of Acquired Immune Deficiency Syn...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HEVESI, LASZLO, BOLLEN, ALEX, DEMONTE, DOMINIQUE, DE WALQUE, STEPHANE, CAUVIN, CHRISTINE, JACQUET, ALAIN, VAN LINT, CARINE, BOLAND, SANDRO, DURANT, FRANCOIS, BURNY, ARSENE, GEORGES, BENOIT, LE VAN, KIET
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to 2-Pyridinone derivatives, more specifically 5-ethyl-6-methyl-2-pyridinone derivatives, according to general formula I that inhibit human immunodeficiency virus type 1 (HIV-1) replication and are therefore of interest in the treatment of Acquired Immune Deficiency Syndrome (AIDS). The present invention further relates to the synthesis of said compounds and their use, with or without other pharmaceutical agents, in the treatment of AIDS and viral infections by HIV-1. La présente invention concerne des dérivés de 2-pyridinone, plus spécifiquement des dérivés de 5-éthyl-6-méthyl-2-pyridinone, selon le formule générale (I) inhibant la réplication du virus de l'immunodéficience humaine de type 1 (VIH-1) lesquels sont par conséquent utiles dans le traitement du syndrome d'immunodéficience acquise (SIDA). La présente invention concerne également la synthèse desdits composés ainsi que leur utilisation, avec ou sans autres agents pharmaceutiques, dans le traitement du SIDA et d'infections virales à VIH-1.